AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17067370 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery training (daily mental rehearsal of movements with affected arm for 4 weeks)
Number of subjects: 135
Study 17067370 — intervention group
Group type: COMPARATOR
Intervention: Non-motor mental rehearsal (closely supervised)
Number of subjects: 135
Study 17067370 — intervention group
Group type: COMPARATOR
Intervention: No training program (control group)
Number of subjects: 135
Study 15603467 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic display AAC technologies in a contextual scene format
Number of subjects: 10
Study 15603467 — intervention group
Group type: COMPARATOR
Intervention: Dynamic display AAC technologies in a grid format
Number of subjects: 10
Study 10617781 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological recoding
Number of subjects: 1
Study 10617781 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthographic lexical representations
Number of subjects: 1
Study 10617781 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit phonological recoding process
Number of subjects: 1
Study 9106560 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled magnesium sulfate (4 mL; 286 mOsm)
Number of subjects: 10
Study 9106560 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 10
Study 8245054 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip replacement with cement
Number of subjects: 188
Study 8245054 — intervention group
Group type: COMPARATOR
Intervention: Total hip replacement without cement
Number of subjects: 188
Study 3545476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 94
Study 3545476 — intervention group
Group type: COMPARATOR
Intervention: Control (tobramycin plus ticarcillin)
Number of subjects: 94
Study 28602935 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard KT tension (n = 26)
Number of subjects: 75
Study 28602935 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased KT tension (n = 25)
Number of subjects: 75
Study 28602935 — intervention group
Group type: COMPARATOR
Intervention: No KT tension (n = 24)
Number of subjects: 75
Study 27229354 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendon (PT) autograft
Number of subjects: 193
Study 27229354 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendon (HT) autograft
Number of subjects: 193
Study 27229354 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 193
Study 24720885 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM group (n = 16)
Number of subjects: 44
Study 24720885 — intervention group
Group type: COMPARATOR
Intervention: Lean group (n = 15)
Number of subjects: 44
Study 24720885 — intervention group
Group type: COMPARATOR
Intervention: Obese group without GDM (n = 13)
Number of subjects: 44
Study 23602798 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaBic) 60 mEq/day for 3 days
Number of subjects: 16
Study 23602798 — intervention group
Group type: COMPARATOR
Intervention: Potassium citrate (KCit) 60 mEq/day for 3 days
Number of subjects: 16
Study 20625021 — intervention group
Group type: EXPERIMENTAL
Intervention: Severely serum 25(OH)D deficient (levels <25 nmol/L)
Number of subjects: 858
Study 20625021 — intervention group
Group type: COMPARATOR
Intervention: Sufficient levels of 25(OH)D (>/=75 nmol/L)
Number of subjects: 858
Study 21197285 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive lumiracoxib 400 mg
Number of subjects: 0
Study 21197285 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative lumiracoxib 400 mg
Number of subjects: 0
Study 21197285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16603063 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and oral prednisolone
Number of subjects: 210
Study 14740601 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous verapamil (0.1 mg/kg)
Number of subjects: 0
Study 11310385 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted diet (Group I, 20 patients)
Number of subjects: 45
Study 11310385 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein restricted diet (Group II, 25 patients, 0.6 g/kg/day, 50% high biological value)
Number of subjects: 45
Study 9307742 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiludronate 200 mg once daily
Number of subjects: 0
Study 9307742 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiludronate 400 mg once daily
Number of subjects: 0
Study 9307742 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiludronate 600 mg once daily
Number of subjects: 0
Study 9307742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9307742 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiludronate (all doses)
Number of subjects: 0
Study 9307742 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiludronate
Number of subjects: 0
Study 8346591 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxon 4-0 sutures
Number of subjects: 50
Study 8346591 — intervention group
Group type: COMPARATOR
Intervention: Vicryl 3-0 sutures
Number of subjects: 50
Study 3520902 — intervention group
Group type: EXPERIMENTAL
Intervention: gentamicin and metronidazole
Number of subjects: 86
Study 3520902 — intervention group
Group type: EXPERIMENTAL
Intervention: moxalactam
Number of subjects: 86
Study 29114972 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA and double induction intensified by high-dose cytosine arabinoside (HD ara‐C)
Number of subjects: 80
Study 29114972 — intervention group
Group type: COMPARATOR
Intervention: ATRA and anthracyclines
Number of subjects: 80
Study 26884390 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0
Study 26884390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24713426 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFE Children intervention (n = 232)
Number of subjects: 424
Study 24713426 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFE Children booster intervention (n = 101)
Number of subjects: 424
Study 24713426 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 192)
Number of subjects: 424
Study 24071751 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based education program (3-hour lecture, 3-hour clinical training, 2-hour simulation)
Number of subjects: 49
Study 24071751 — intervention group
Group type: COMPARATOR
Intervention: Control group (3-hour lecture only)
Number of subjects: 49
Study 20507285 — intervention group
Group type: EXPERIMENTAL
Intervention: B-mode ultrasound system with a linear transducer of 7.5 MHz for evaluation of flow-mediated vasodilation in brachial artery (FMV)
Number of subjects: 171
Study 20507285 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 171
Study 20507285 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cholesterol
Number of subjects: 171
Study 20507285 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of diabetes
Number of subjects: 171
Study 20507285 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemia
Number of subjects: 171
Study 18677147 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medicine practices in menopausal management
Number of subjects: 0
Study 18677147 — intervention group
Group type: COMPARATOR
Intervention: Randomized clinical trials (RCTs)
Number of subjects: 0
Study 15776267 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injections (Hylan G-F 20), 3 intra-articular injections at one-week intervals
Number of subjects: 105
Study 15776267 — intervention group
Group type: COMPARATOR
Intervention: Progressive knee exercises (PE) for 6 weeks
Number of subjects: 105
Study 15776267 — intervention group
Group type: COMPARATOR
Intervention: Progressive knee exercises (PE)
Number of subjects: 105
Study 14639556 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise (n=10)
Number of subjects: 30
Study 14639556 — intervention group
Group type: EXPERIMENTAL
Intervention: On-land exercise (n=10)
Number of subjects: 30
Study 14639556 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 30
Study 12012627 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 + TMG (estradiol + trimegestone)
Number of subjects: 634
Study 12012627 — intervention group
Group type: COMPARATOR
Intervention: EV + NG (estradiol valerate + norgestrel)
Number of subjects: 634
Study 12012627 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 + TMG
Number of subjects: 634
Study 12012627 — intervention group
Group type: COMPARATOR
Intervention: EV + NG
Number of subjects: 634
Study 12012627 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 634
Study 10734527 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-convulsive therapy (ECT)
Number of subjects: 70
Study 10734527 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 70
Study 8724322 — intervention group
Group type: EXPERIMENTAL
Intervention: IUDs
Number of subjects: 0
Study 1955002 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) (250 micrograms.puff‐1), beginning with 1,000 micrograms daily
Number of subjects: 124
Study 1955002 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP)
Number of subjects: 124
Study 1955002 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 124
Study 6122339 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10
Study 6122339 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 10
Study 6122339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 4084668 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dose of cibenzoline (8.00 am)
Number of subjects: 8
Study 4084668 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening dose of cibenzoline (10.00 pm)
Number of subjects: 8
Study 30449071 — intervention group
Group type: EXPERIMENTAL
Intervention: Local treatment: surgery radiotherapy (55%)
Number of subjects: 47
Study 30449071 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive surgery (28%)
Number of subjects: 47
Study 30449071 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (17%)
Number of subjects: 47
Study 30449071 — intervention group
Group type: EXPERIMENTAL
Intervention: Postchemotherapy surgery without postoperative radiotherapy (PORT)
Number of subjects: 47
Study 30449071 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial surgery without previous chemotherapy, with PORT
Number of subjects: 47
Study 30449071 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 47
Study 27050045 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga Therapy (YT)
Number of subjects: 69
Study 27050045 — intervention group
Group type: COMPARATOR
Intervention: Standard Medical Care (SMC)
Number of subjects: 69
Study 25697379 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga program
Number of subjects: 20
Study 25697379 — intervention group
Group type: COMPARATOR
Intervention: Exercise program
Number of subjects: 20
Study 22905811 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/day
Number of subjects: 422
Study 22905811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study 20600013 — intervention group
Group type: COMPARATOR
Intervention: Peg‐IFNα‐2a 180 μg every week
Number of subjects: 1331
Study 20600013 — intervention group
Group type: EXPERIMENTAL
Intervention: albIFN 900 μg every 2 weeks
Number of subjects: 1331
Study 20600013 — intervention group
Group type: EXPERIMENTAL
Intervention: albIFN 1200 μg every 2 weeks
Number of subjects: 1331
Study 18198165 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Motion Apparatus (CMA) treatment, thrice-weekly 30-min treatments for 12 weeks
Number of subjects: 50
Study 18198165 — intervention group
Group type: COMPARATOR
Intervention: Control group, single-blind control of equal duration and intensity
Number of subjects: 50
Study 16429317 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone (45 mg/day)
Number of subjects: 22
Study 16429317 — intervention group
Group type: COMPARATOR
Intervention: glibenclamide (5 mg/day)
Number of subjects: 22
Study 14738027 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-125 level > or = 43.1 U/mL in women with symptoms of imminent abortion
Number of subjects: 200
Study 14738027 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-125 level threshold of 66.5 U/mL for patients with bleeding of > or = 3 days
Number of subjects: 200
Study 14738027 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum beta-hCG levels
Number of subjects: 200
Study 14738027 — intervention group
Group type: COMPARATOR
Intervention: CA-125 levels in groups II and III
Number of subjects: 200
Study 10941601 — intervention group
Group type: EXPERIMENTAL
Intervention: Achillea drops (hydroalcoholic extract), 15-20 drops twice daily for more than 6 months
Number of subjects: 120
Study 9196140 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (800 mg by mouth daily)
Number of subjects: 90
Study 9196140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 1588260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg orally daily)
Number of subjects: 107
Study 1588260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 3709630 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ), 10 mg kg‐1
Number of subjects: 12
Study 30965384 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention (76-page psychoeducational resource and three telephone-based sessions with a psychologist)
Number of subjects: 164
Study 30965384 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 164
Study 30555717 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar muscle stabilisation exercises (LMSE)
Number of subjects: 32
Study 30555717 — intervention group
Group type: COMPARATOR
Intervention: Back endurance-resistance exercises (BERE)
Number of subjects: 32
Study 27655507 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET‐CT
Number of subjects: 70
Study 27655507 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 70
Study 25093998 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg twice daily) and Simvastatin (40 mg twice daily)
Number of subjects: 18
Study 25093998 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg twice daily), Simvastatin (40 mg twice daily), and NaRLA (600 mg three times daily)
Number of subjects: 18
Study 25093998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 22445597 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel with PPI
Number of subjects: 302
Study 22445597 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine with PPI
Number of subjects: 302
Study 20360503 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergometer cycling
Number of subjects: 362
Study 20360503 — intervention group
Group type: COMPARATOR
Intervention: Control (no ergometer cycling)
Number of subjects: 362
Study 18683819 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg Se/day as high-Se-yeast
Number of subjects: 501
Study 18683819 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg Se/day as high-Se-yeast
Number of subjects: 501
Study 18683819 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 microg Se/day as high-Se-yeast
Number of subjects: 501
Study 18683819 — intervention group
Group type: COMPARATOR
Intervention: Placebo-yeast
Number of subjects: 501
Study 16179660 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (0.5 mg sublingually)
Number of subjects: 14
Study 16179660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 12660937 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc and placebo (Z group)
Number of subjects: 0
Study 12660937 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A and zinc (AZ group)
Number of subjects: 0
Study 12660937 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A and placebo (A group)
Number of subjects: 0
Study 12660937 — intervention group
Group type: COMPARATOR
Intervention: Both placebos (P group)
Number of subjects: 0
Study 10759624 — intervention group
Group type: EXPERIMENTAL
Intervention: nabumetone (1500-2000 mg/day)
Number of subjects: 694
Study 10759624 — intervention group
Group type: COMPARATOR
Intervention: diclofenac SR (100 mg/day)
Number of subjects: 694
Study 10759624 — intervention group
Group type: COMPARATOR
Intervention: piroxicam (20-30 mg/day)
Number of subjects: 694
Study 8703252 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 3407
Study 8703252 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 3407
Study 8703252 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction as part of expectant management
Number of subjects: 3407
Study 8703252 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous or induced labor as part of induction policy
Number of subjects: 3407
Study 1385087 — intervention group
Group type: EXPERIMENTAL
Intervention: Oddball paradigm with 1 deviant (P = 0.20)
Number of subjects: 0
Study 1385087 — intervention group
Group type: EXPERIMENTAL
Intervention: Oddball paradigm with 2 deviants (each with a probability of 0.10)
Number of subjects: 0
Study 1385087 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular alternation of tones of 2 pitches (P = 0.20)
Number of subjects: 0
Study 1385087 — intervention group
Group type: EXPERIMENTAL
Intervention: Random presentation of tones of 5 different pitches (P = 0.20)
Number of subjects: 0
Study 1385087 — intervention group
Group type: EXPERIMENTAL
Intervention: Count conditions (where infrequent events were designated as targets)
Number of subjects: 0
Study 1385087 — intervention group
Group type: EXPERIMENTAL
Intervention: Count conditions
Number of subjects: 0
Study 6693322 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory loads (I)
Number of subjects: 6
Study 6693322 — intervention group
Group type: COMPARATOR
Intervention: Expiratory loads (E)
Number of subjects: 6
Study 6693322 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory and Expiratory loads (I and E)
Number of subjects: 6
Study 28825422 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (1 mg/kg) during encoding
Number of subjects: 60
Study 28825422 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (1 mg/kg) during retrieval
Number of subjects: 60
Study 28825422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28636405 — intervention group
Group type: EXPERIMENTAL
Intervention: Home respiratory polygraphy
Number of subjects: 430
Study 28636405 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography
Number of subjects: 430
Study 25394762 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 µg/kg) for 10 min preoperatively
Number of subjects: 37
Study 25394762 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (control)
Number of subjects: 37
Study 25394762 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.9% normal saline)
Number of subjects: 37
Study 25394762 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group
Number of subjects: 37
Study 22260216 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 200 mg (p.o. given as a 2-hour pre-treatment)
Number of subjects: 8
Study 22260216 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (20 and 40 mg/70 kg oral; 15 and 30 mg/70 kg intranasal)
Number of subjects: 8
Study 21228691 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumented spinal fusion
Number of subjects: 51
Study 21228691 — intervention group
Group type: COMPARATOR
Intervention: Uninstrumented spinal fusion
Number of subjects: 51
Study 18838046 — intervention group
Group type: COMPARATOR
Intervention: Epidural neostigmine (0.3 mg) with 10 mL of 0.75% ropivacaine
Number of subjects: 60
Study 18838046 — intervention group
Group type: COMPARATOR
Intervention: Systemic dexmedetomidine (loading dose of 1 mug kg‐1 over 10 min followed by 0.4 mug kg‐1 h‐1)
Number of subjects: 60
Study 18838046 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administered neostigmine and dexmedetomidine
Number of subjects: 60
Study 16809238 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone calls promoting treatment adherence (initial call and biweekly calls)
Number of subjects: 271
Study 16809238 — intervention group
Group type: COMPARATOR
Intervention: Control group received only initial and final telephone calls
Number of subjects: 271
Study 16809238 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received three packages of salmeterol/fluticasone for 3 months
Number of subjects: 271
Study 12939779 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression models with baseline adjustment
Number of subjects: 0
Study 12939779 — intervention group
Group type: COMPARATOR
Intervention: Logistic regression models without baseline adjustment
Number of subjects: 0
Study 11037047 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving images
Number of subjects: 0
Study 11037047 — intervention group
Group type: COMPARATOR
Intervention: Still images
Number of subjects: 0
Study 8896531 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa vaccine
Number of subjects: 0
Study 1636474 — intervention group
Group type: EXPERIMENTAL
Intervention: High KCAL preload
Number of subjects: 0
Study 1636474 — intervention group
Group type: COMPARATOR
Intervention: No preload
Number of subjects: 0
Study 3975490 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaditen
Number of subjects: 10
Study 3975490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30817782 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-talking rule (patients requested not to talk)
Number of subjects: 263
Study 30817782 — intervention group
Group type: COMPARATOR
Intervention: Talking condition (patients allowed to talk)
Number of subjects: 263
Study 30817782 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-talking rule
Number of subjects: 263
Study 30817782 — intervention group
Group type: COMPARATOR
Intervention: Talking condition
Number of subjects: 263
Study 28937313 — intervention group
Group type: EXPERIMENTAL
Intervention: MiECC with cell-saver
Number of subjects: 0
Study 28937313 — intervention group
Group type: COMPARATOR
Intervention: MiECC with direct re-transfusion of shed blood (Control)
Number of subjects: 0